Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities
Open Access
- 1 January 2011
- journal article
- review article
- Published by Medknow in Journal of Pharmacy and Bioallied Sciences
- Vol. 3 (3) , 350-60
Abstract
The long history of Cannabis sativa had its development stimulated and oriented for medicine after the discovery and chemical characterization of its main active ingredient, the 9-tetrahydrocannabinol (9-THC). Consequently, a binding site for 9-THC was identified in rat brains and the first cannabinoid receptor (CB1) was cloned, followed by the CB2 and by the discover of two endogenous agonists: anandamide and 2-arachidonoyl glycerol. Cannabinoid receptors, endocannabinoids and the enzymes that catalyze its synthesis and degradation constitute the endocannabinoid system (ECS), which plays an important role in the cardiovascular system. In vivo experiments with rats have demonstrated the action of anandamide and 2-AG on the development of atherosclerotic plaque, as well as an effect on heart rate, blood pressure, vasoactivity and energy metabolism (action in dyslipidemia and obesity). Recent studies with an antagonist of CB1 receptors showed that the modulation of ECS can play an important role in reducing cardiovascular risk in obese and dyslipidemic patients. Similarly, studies in rats have demonstrated the action of CB2 receptors in adhesion, migration, proliferation and function of immune cells involved in the atherosclerotic plaque formation process. The evidence so far gathered shows that the modulation of ECS (as agonism or antagonism of its receptors) is an enormous potential field for research and intervention in multiple areas of human pathophysiology. The development of selective drugs for the CB1 and CB2 receptors may open a door to new therapeutic regimens.This review article aims to address the key findings and evidences on the modulation of ECS, in order to prospect future forms of therapeutic intervention at the cardiovascular level. A recent, emerging, controversial and of undoubted scientific interest subject, which states as a potential therapeutic target to reach in the 21 st century.Keywords
This publication has 105 references indexed in Scilit:
- Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonistsEuropean Journal of Endocrinology, 2009
- CB2receptor‐mediated migration of immune cells: it can go either wayBritish Journal of Pharmacology, 2008
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2008
- Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolaseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJACC, 2007
- Cannabinoid CB2 Receptor Activation Decreases Cerebral Infarction in a Mouse Focal Ischemia/Reperfusion ModelJournal of Cerebral Blood Flow & Metabolism, 2007
- Endothelium‐dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2‐arachidonoylglycerolBritish Journal of Pharmacology, 2007
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemiaNeuroscience, 2004